Kiora Pharmaceuticals Inc
KPRX
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
332 Encinitas Boulevard
Suite 102
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
Fuel volatility can lead to short-term earnings swings but all players bear the cost almost equally.
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,173.60 | 36.60 | -0.40% |
| CAC 40 | 8,294.03 | 19.46 | 0.24% |
| DAX 40 | 24,133.04 | 66.34 | 0.28% |
| Dow JONES (US) | 48,372.23 | 91.49 | -0.19% |
| FTSE 100 | 10,595.03 | 35.45 | 0.34% |
| HKSE | 26,394.26 | 521.94 | 2.02% |
| NASDAQ | 23,946.18 | 69.84 | -0.29% |
| Nikkei 225 | 59,518.34 | 1,640.95 | 2.84% |
| NZX 50 Index | 13,066.06 | 48.80 | 0.37% |
| S&P 500 | 7,013.85 | 9.10 | -0.13% |
| S&P/ASX 200 | 8,955.00 | 56.40 | -0.63% |
| SSE Composite Index | 4,055.55 | 28.34 | 0.70% |